JP5712126B2 - 遅延型追加刺激免疫処置に対する迅速な応答 - Google Patents
遅延型追加刺激免疫処置に対する迅速な応答 Download PDFInfo
- Publication number
- JP5712126B2 JP5712126B2 JP2011515663A JP2011515663A JP5712126B2 JP 5712126 B2 JP5712126 B2 JP 5712126B2 JP 2011515663 A JP2011515663 A JP 2011515663A JP 2011515663 A JP2011515663 A JP 2011515663A JP 5712126 B2 JP5712126 B2 JP 5712126B2
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- boosting
- immunogen
- immune response
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000004044 response Effects 0.000 title claims description 9
- 230000003053 immunization Effects 0.000 title description 17
- 238000002649 immunization Methods 0.000 title description 16
- 230000003111 delayed effect Effects 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims description 169
- 230000002163 immunogen Effects 0.000 claims description 166
- 230000028993 immune response Effects 0.000 claims description 108
- 229960005486 vaccine Drugs 0.000 claims description 67
- 230000001681 protective effect Effects 0.000 claims description 57
- 230000037452 priming Effects 0.000 claims description 51
- 239000002671 adjuvant Substances 0.000 claims description 49
- 208000015181 infectious disease Diseases 0.000 claims description 39
- 206010022000 influenza Diseases 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 31
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 30
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 30
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 30
- 229940031439 squalene Drugs 0.000 claims description 30
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 30
- 239000000839 emulsion Substances 0.000 claims description 19
- 239000007764 o/w emulsion Substances 0.000 claims description 19
- 239000004094 surface-active agent Substances 0.000 claims description 19
- 239000000568 immunological adjuvant Substances 0.000 claims description 18
- 230000005875 antibody response Effects 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 230000036039 immunity Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 8
- 210000000987 immune system Anatomy 0.000 claims description 7
- 230000003472 neutralizing effect Effects 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 208000037797 influenza A Diseases 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 244000052769 pathogen Species 0.000 description 83
- 230000001717 pathogenic effect Effects 0.000 description 77
- 238000002255 vaccination Methods 0.000 description 11
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 210000001806 memory b lymphocyte Anatomy 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000035606 childbirth Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 4
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 4
- -1 citrate ions Chemical class 0.000 description 4
- 229960003971 influenza vaccine Drugs 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 241000193163 Clostridioides difficile Species 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 241000193985 Streptococcus agalactiae Species 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 241000589291 Acinetobacter Species 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 108010060123 Conjugate Vaccines Proteins 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 229940032024 DPT vaccine Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229940032047 Tdap vaccine Drugs 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 108010029566 avian influenza A virus hemagglutinin Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 229940031670 conjugate vaccine Drugs 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 241000252870 H3N2 subtype Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 229940124870 Hepatitis A virus vaccine Drugs 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 229940124872 Hepatitis B virus vaccine Drugs 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 229940124859 Rotavirus vaccine Drugs 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960005097 diphtheria vaccines Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 229940029583 inactivated polio vaccine Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940095293 mumps vaccine Drugs 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960003131 rubella vaccine Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 229960002766 tetanus vaccines Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 229940021648 varicella vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13314008P | 2008-06-25 | 2008-06-25 | |
| US61/133,140 | 2008-06-25 | ||
| PCT/IB2009/006260 WO2009156852A1 (en) | 2008-06-25 | 2009-06-25 | Rapid responses to delayed booster immunisations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011525902A JP2011525902A (ja) | 2011-09-29 |
| JP2011525902A5 JP2011525902A5 (enExample) | 2012-08-09 |
| JP5712126B2 true JP5712126B2 (ja) | 2015-05-07 |
Family
ID=41171092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515663A Expired - Fee Related JP5712126B2 (ja) | 2008-06-25 | 2009-06-25 | 遅延型追加刺激免疫処置に対する迅速な応答 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9421251B2 (enExample) |
| EP (1) | EP2310045A1 (enExample) |
| JP (1) | JP5712126B2 (enExample) |
| CA (1) | CA2729248A1 (enExample) |
| WO (1) | WO2009156852A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| JP5911870B2 (ja) | 2010-08-31 | 2016-04-27 | ノバルティス アーゲー | 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| AR086199A1 (es) | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| JP2014522842A (ja) | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
| US11058762B2 (en) | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| WO2021255690A2 (en) | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| ES2399386T3 (es) * | 2001-04-05 | 2013-04-01 | Novartis Vaccines And Diagnostics, Inc. | Aumento de la inmunidad de las mucosas tras sensibilización parenteral |
| US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
| TWI365074B (en) | 2004-10-07 | 2012-06-01 | Wyeth Corp | Multivalent avian influenza vaccines |
| WO2006050394A2 (en) * | 2004-11-01 | 2006-05-11 | Novartis Vaccines And Diagnostics Inc. | Combination approaches for generating immune responses |
| DK1861120T3 (en) * | 2005-03-23 | 2016-07-25 | Glaxosmithkline Biologicals Sa | Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response |
| NZ594482A (en) | 2005-11-04 | 2012-11-30 | Novartis Vaccines & Diagnostic | Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant |
| EP1945253A2 (en) | 2005-11-04 | 2008-07-23 | Novartis Vaccines and Diagnostics S.r.l. | Adminstration routes for priming/boosting with influenza vaccines |
| WO2007130330A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Polyvalent influenza virus-like particle (vlp) compositions |
| US20080014217A1 (en) | 2006-07-17 | 2008-01-17 | Emmanuel Jules Hanon | Influenza vaccine |
| EP2043682B1 (en) | 2006-07-17 | 2014-04-02 | GlaxoSmithKline Biologicals S.A. | Influenza vaccine |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
-
2009
- 2009-06-25 EP EP09769663A patent/EP2310045A1/en not_active Withdrawn
- 2009-06-25 CA CA2729248A patent/CA2729248A1/en not_active Abandoned
- 2009-06-25 US US12/999,848 patent/US9421251B2/en not_active Expired - Fee Related
- 2009-06-25 JP JP2011515663A patent/JP5712126B2/ja not_active Expired - Fee Related
- 2009-06-25 WO PCT/IB2009/006260 patent/WO2009156852A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US9421251B2 (en) | 2016-08-23 |
| CA2729248A1 (en) | 2009-12-30 |
| US20110150931A1 (en) | 2011-06-23 |
| JP2011525902A (ja) | 2011-09-29 |
| WO2009156852A1 (en) | 2009-12-30 |
| EP2310045A1 (en) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9421251B2 (en) | Rapid responses to delayed booster immunisations | |
| US20230390381A1 (en) | Immunogenic combinations | |
| EP0528859B1 (en) | Oral vaccine comprising antigen surface-associated with red blood cells | |
| TWI457133B (zh) | 新穎組合物 | |
| ES2307494T3 (es) | Vacuna del virus de la gripe inactivo para su administracion via nasalu oral. | |
| US20090081253A1 (en) | Composition | |
| ES2627082T3 (es) | Procedimiento de producción de una vacuna contra la gripe | |
| ES2398451T3 (es) | Coadyuvante para vacunas | |
| EA016417B1 (ru) | Способ получения вакцины | |
| JP2003522802A (ja) | プロテオソーム・インフルエンザ・ワクチン | |
| JP2019112448A (ja) | ナイーブな対象のためのワクチン組成物 | |
| SG173194A1 (en) | Inactivated dengue virus vaccine with aluminium-free adjuvant | |
| CN119700949A (zh) | 一种重组呼吸道合胞病毒疫苗及其制备方法和应用 | |
| JP5918870B2 (ja) | インフルエンザに対する改善されたワクチン接種 | |
| US20130315951A1 (en) | Compositions and methods for stimulating an immune response against infectious agents | |
| JP2015509520A (ja) | 狂犬病ウイルス免疫原のアジュバント化製剤 | |
| CN107469075B (zh) | 一种高剂量四价流感疫苗组合物 | |
| JP2023091085A (ja) | 粘膜アジュバント | |
| Backx et al. | Immunization | |
| Maryam et al. | 2773. Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine | |
| Nelson et al. | 2772. HCMV gB Ectodomain Subunit and gB mRNA Vaccines Reduce AD-3 Immunodominance and Elicit More Durable Antibody Responses Than gB/MF59 Immunization | |
| Barrett | Licensed vaccines for humans | |
| Scott et al. | Live Attenuated Influenza Vaccine (Fluenz [superscript](TM)[/superscript]) | |
| 李秀玲 et al. | Development of RSV Vaccines | |
| BRPI0609519A2 (pt) | composição, uso de uma composição, método de vacinação, uso de um antìgeno, e, método para a preparação de uma composição imunogênica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120622 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120622 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131007 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140106 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140526 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140714 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141224 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150123 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150219 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150309 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5712126 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |